Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to pioneering tumor-activated immuno-oncology (I-O) therapies aimed at significantly improving outcomes for cancer patients. The company's name, Xilio, is derived from the Latin term 'ex nihilo,' meaning creation or big bang, symbolizing its innovative approach.
Xilio leverages its proprietary platform to develop a pipeline of novel, tumor-activated clinical and preclinical I-O molecules. These include engineered antibodies, cytokines, and chemokines, all designed to localize anti-tumor activity within the tumor microenvironment, thus optimizing the therapeutic index and minimizing systemic side effects.
Key Products and Developments:
- XTX202: An investigational tumor-activated, engineered IL-2 molecule designed to stimulate CD8+ effector T cells and natural killer (NK) cells without stimulating regulatory T cells. Recent Phase 1/2 data showed a 50% disease control rate at higher doses, and it is currently being evaluated in a Phase 2 trial for melanoma and renal cell carcinoma.
- XTX101: A tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is being evaluated in combination with atezolizumab in a Phase 1/2 clinical trial for advanced solid tumors.
- XTX301: An engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. XTX301 is in a Phase 1 clinical trial, and Xilio has recently entered into an exclusive license agreement with Gilead Sciences for its development.
Recent Achievements:
- XTX202 Phase 1 monotherapy dose-escalation success at a dose level of 4.0 mg/kg, with plans to explore combination therapy opportunities.
- The company announced a strategic partnership with Gilead Sciences to accelerate the development of XTX301.
- Financial results indicate that Xilio's existing cash and cash equivalents can fund operations into the second quarter of 2025, bolstered by recent private placements and upfront payments from strategic partnerships.
For more detailed information on Xilio Therapeutics and its pipeline of tumor-activated I-O therapies, visit www.xiliotx.com.
Xilio Therapeutics (Nasdaq: XLO) reported significant progress in its clinical-stage pipeline, showcasing tumor-activated therapies, XTX202 and XTX301. The ongoing Phase 1 trial for XTX202 has successfully reached a target dose of 1 mg/kg, showing increased CD8+ effector and NK cells without vascular leak syndrome. XTX301 received FDA IND clearance, with patient enrollment expected in early 2023. The company reported $139.1 million in cash as of September 30, 2022, which is projected to last until Q2 2024, despite a net loss of $19.8 million for Q3 2022.
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced its participation in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on November 11, 2022, at 1:40 p.m. ET. The event can be accessed via live webcast in the Investors & Media section of its website, with a replay available for 30 days post-presentation. Xilio focuses on developing tumor-activated immuno-oncology therapies, using its GPS platform to create biologics targeting the tumor microenvironment, aiming for enhanced anti-tumor activity. Key product candidates include XTX101 and XTX202.
On September 22, 2022, Xilio Therapeutics (Nasdaq: XLO) announced its participation in a fireside chat at the Guggenheim Nantucket Therapeutics Conference, scheduled for September 29, 2022, at 10:15 a.m. ET. A live webcast will be available on the company’s website, with access under the “Events & Presentations” section. This presentation will be archived for 30 days. Xilio is focused on developing tumor-selective immuno-oncology therapies aimed at improving cancer patient outcomes through its proprietary GPS platform.
Xilio Therapeutics has appointed Tomas J. Heyman to its board of directors, enhancing the team with nearly 40 years of biopharmaceutical leadership experience. Heyman previously worked at Johnson & Johnson, overseeing substantial investments in over 120 companies. Additionally, John Maraganore, former CEO of Alnylam Pharmaceuticals, joins as a strategic advisor. These appointments aim to advance Xilio's tumor-selective immunotherapy programs, leveraging their expertise to drive value creation and innovation in cancer treatment.
Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, will participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 2:55 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days post-event. Xilio is advancing its proprietary GPS platform to engineer tumor-selective cytokines and checkpoint inhibitors, including clinical-stage programs XTX101 and XTX202.
Xilio Therapeutics (Nasdaq: XLO) provided an update on its clinical trials and financials on August 9, 2022. XTX101, a tumor-selective anti-CTLA-4, has exceeded its target dose in a Phase 1 trial, with plans for a Phase 2 trial in MSS colorectal cancer. The company reported a cash position of $159.4 million as of June 30, 2022, expected to sustain operations into the first half of 2024. The second quarter net loss increased to $24.6 million, reflecting a rise in general and administrative expenses. Upcoming milestones include critical data releases for XTX101 and XTX202 in 2023.
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced key leadership changes on June 16, 2022. Martin Huber, M.D., is promoted to president while continuing as head of R&D. Paul Clancy is elected chair of the board, succeeding Dan Lynch, who will serve as a strategic advisor. Clancy has been part of the board since July 2020 and brings extensive financial management experience. Additionally, Robert Ross, M.D., joins the board, enhancing Xilio’s oncology expertise. These leadership changes aim to improve Xilio’s strategic direction and advance its tumor-selective immuno-oncology programs.
Xilio Therapeutics, a biotechnology company focused on tumor-selective immuno-oncology therapies, announced that Dr. Marty Huber will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 2:30 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for 30 days. Xilio is advancing its proprietary GPS platform to create targeted therapies like XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, aiming to enhance anti-tumor activity while minimizing systemic effects.
Xilio Therapeutics, Inc. (Nasdaq: XLO) has appointed Stacey Davis as its new chief business officer to enhance corporate and business development strategies for future growth. With over 25 years in the life sciences sector, Davis comes from Novartis Oncology and has a proven track record in oncology and immunology. Xilio is advancing its pipeline of tumor-selective immunotherapies, with clinical data readouts expected later this year. The company aims to improve cancer treatment outcomes through its innovative geographically precise solutions (GPS) platform.
Xilio Therapeutics (Nasdaq: XLO) announced pipeline and financial highlights for Q1 2022, showcasing ongoing clinical trials for XTX202 and XTX101, with preliminary data expected later in 2022.
The company maintains a strong financial position with $177 million in cash, expected to fund operations into H1 2024. R&D expenses rose to $14.9 million, while net loss was $21.4 million for the quarter. Future prospects include submitting an IND for XTX301, a tumor-selective IL-12, later this year.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
What is Xilio Therapeutics, Inc.?
What does the name Xilio mean?
What are the key products developed by Xilio?
What is the focus of Xilio's technology platform?
What recent achievements has Xilio reported?
What is XTX202?
What is XTX101?
What is XTX301?
How can I learn more about Xilio Therapeutics?